1276 — Jiangsu Hengrui Pharmaceuticals Co Share Price
- HK$356.27bn
- HK$330.54bn
- CNY27.98bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 7.26 | ||
Price to Tang. Book | 8.18 | ||
Price to Free Cashflow | 73.9 | ||
Price to Sales | 11.68 | ||
EV to EBITDA | 43.18 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 16.57% | ||
Return on Equity | 15.4% | ||
Operating Margin | 27.2% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 27,734.6 | 25,905.53 | 21,275.27 | 22,819.78 | 27,984.61 | n/a | n/a | 3.74% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +18.64 | -28.7 | -12.06 | +10.63 | +44.8 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
Directors
- Yunshu Zhou CHM (49)
- Jianjun Liu CFO (44)
- Hongbin Dai DGM (44)
- Jieping Sun DGM (50)
- Lianshan Zhang DGM (60)
- Sumei Jiang DGM (57)
- Cheng Liao DGM (46)
- Yaping Shen DGM (58)
- Xugen Sun DGM (52)
- Weikang Tao DGM (57)
- Hongsen Wang DGM (51)
- Kaihong Yuan DGM (55)
- Yuehong Zhang DGM (46)
- Jianjun Zou DGM (49)
- Xiaohan Liu SEC (35)
- Congzhao Guo DRC (48)
- Piaoyang Sun DRC (63)
- Yuanchao Li IND (69)
- Qian Wang IND (46)
- Shuang Xue IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 28th, 1997
- Public Since
- October 18th, 2000
- No. of Shareholders
- 446,639
- No. of Employees
- 20,238
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 6,379,002,274

- Address
- No.7 Kunlunshan Road, LIANYUNGANG, 222000
- Web
- https://www.hengrui.com/
- Phone
- +86 2161053323
- Contact
- Xiaohan Liu
- Auditors
- Ernst & Young LLP
Similar to 1276
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories (Tianjin) Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 17:48 UTC, shares in Jiangsu Hengrui Pharmaceuticals Co are trading at HK$58.50. This share price information is delayed by 15 minutes.
Shares in Jiangsu Hengrui Pharmaceuticals Co last closed at HK$58.50 and the price had moved by over the past 365 days. In terms of relative price strength the Jiangsu Hengrui Pharmaceuticals Co share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreThe Jiangsu Hengrui Pharmaceuticals Co dividend yield is 0.37% based on the trailing twelve month period.
Last year, Jiangsu Hengrui Pharmaceuticals Co paid a total dividend of CNY0.20, and it currently has a trailing dividend yield of 0.37%. We do not have any data on when Jiangsu Hengrui Pharmaceuticals Co is to next pay dividends.
We do not have data on when Jiangsu Hengrui Pharmaceuticals Co is to next pay dividends. The historic dividend yield on Jiangsu Hengrui Pharmaceuticals Co shares is currently 0.37%.
To buy shares in Jiangsu Hengrui Pharmaceuticals Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$58.50, shares in Jiangsu Hengrui Pharmaceuticals Co had a market capitalisation of HK$373.17bn.
Here are the trading details for Jiangsu Hengrui Pharmaceuticals Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1276
Based on an overall assessment of its quality, value and momentum Jiangsu Hengrui Pharmaceuticals Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jiangsu Hengrui Pharmaceuticals Co. Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of HK$58.50, shares in Jiangsu Hengrui Pharmaceuticals Co were trading +2.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Jiangsu Hengrui Pharmaceuticals Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$58.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Jiangsu Hengrui Pharmaceuticals Co's management team is headed by:
- Yunshu Zhou - CHM
- Jianjun Liu - CFO
- Hongbin Dai - DGM
- Jieping Sun - DGM
- Lianshan Zhang - DGM
- Sumei Jiang - DGM
- Cheng Liao - DGM
- Yaping Shen - DGM
- Xugen Sun - DGM
- Weikang Tao - DGM
- Hongsen Wang - DGM
- Kaihong Yuan - DGM
- Yuehong Zhang - DGM
- Jianjun Zou - DGM
- Xiaohan Liu - SEC
- Congzhao Guo - DRC
- Piaoyang Sun - DRC
- Yuanchao Li - IND
- Qian Wang - IND
- Shuang Xue - IND